base metals investing Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
base metals investing Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
base metals investing Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
base metals investing Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association 86th Scientific Sessions
base metals investing Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
base metals investing Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
base metals investing Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
base metals investing Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
base metals investing Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
base metals investing Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
